Browse ITGB4

Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Cell membrane; Lipid-anchor. Cell junction, hemidesmosome. Note=Colocalizes with DST at the leading edge of migrating keratinocytes.
Domain PF03160 Calx-beta domain
PF07974 EGF-like domain
PF00041 Fibronectin type III domain
PF07965 Integrin beta tail domain
PF00362 Integrin beta chain VWA domain
PF17205 Integrin plexin domain
Function

Integrin alpha-6/beta-4 is a receptor for laminin. Plays a critical structural role in the hemidesmosome of epithelial cells. Is required for the regulation of keratinocyte polarity and motility. ITGA6:ITGB4 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGA6:ITGB4 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:22351760). ITGA6:ITGB4 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464).

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001704 formation of primary germ layer
GO:0001707 mesoderm formation
GO:0006914 autophagy
GO:0007044 cell-substrate junction assembly
GO:0007160 cell-matrix adhesion
GO:0007229 integrin-mediated signaling pathway
GO:0007369 gastrulation
GO:0007498 mesoderm development
GO:0030198 extracellular matrix organization
GO:0031581 hemidesmosome assembly
GO:0031589 cell-substrate adhesion
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0035878 nail development
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0043062 extracellular structure organization
GO:0043588 skin development
GO:0048332 mesoderm morphogenesis
GO:0048333 mesodermal cell differentiation
GO:0048565 digestive tract development
GO:0048736 appendage development
GO:0055123 digestive system development
GO:0060173 limb development
GO:0072001 renal system development
GO:0097186 amelogenesis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005520 insulin-like growth factor binding
GO:0019838 growth factor binding
GO:0031994 insulin-like growth factor I binding
GO:0038132 neuregulin binding
Cellular Component GO:0008305 integrin complex
GO:0030055 cell-substrate junction
GO:0030056 hemidesmosome
GO:0031252 cell leading edge
GO:0043235 receptor complex
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-1474290: Collagen formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-3000157: Laminin interactions
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-3000170: Syndecan interactions
R-HSA-446107: Type I hemidesmosome assembly
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITGB4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITGB4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITGB4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.660.304
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.70.611
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.680.0428
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4680.279
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6840.817
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1960.959
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1970.734
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6450.525
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4390.72
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5780.75
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0230.993
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.190.259
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITGB4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.517.6-8.10.64
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGB4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGB4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGB4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGB4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITGB4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITGB4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITGB4
Nameintegrin, beta 4
Aliases CD104; CD104 antigen; integrin beta-4 subunit; CD antigen CD104; Integrin beta-4
Chromosomal Location17q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITGB4 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ITGB4.
ID Name Drug Type Targets #Targets
DB05122R1295Small MoleculeITGA4, ITGB4, ITGB73